argenx SE
As of Oct 22, 2026, argenx is in Stage 2, the uptrend phase, now in week 19 (since Jun 10, 2026). It closed at $875.76, 17.3% below its 52-week high and above its 200-day average, which is rising.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is ARGX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ARGX among Biotechnology168th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …168 | ARGX | Stage 2 · wk 19 | 59 | −7.4% |
argenx: quick answers
What stage is argenx in?
As of Oct 22, 2026, argenx (ARGX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 10, 2026 and is in week 19. What the four stages mean
Is argenx in an uptrend?
Yes. argenx is in a Stage 2 uptrend. It trades 2.8% above its 200-day average, which is rising.
How far is argenx from its 52-week high?
argenx closed at $875.76 on Oct 22, 2026, 17.3% below its 52-week high of $1,058.90. Its 52-week low is $663.93.
How has argenx performed over the past year?
As of Oct 22, 2026, argenx is up 4.9% over the past year and up 4.3% so far in 2026.
Which sector and industry is argenx in?
argenx is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.